(IN BRIEF) Ludwig Maximilian University of Munich has received funding from the German Research Foundation for a new Collaborative Research Centre focused on the relationship between thrombosis and inflammation. The project, known as CRC 1784 InTraC, aims to investigate how … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, Science, Technology
Tagged autoimmune disease, cardiovascular disease, cell therapy, charité, Collaborative Research Centre, COVID-19, CRC 1784, DFG, Dresden University of Technology, epigenetics, gene therapy, German Research Foundation, heart attack, Helmholtz Munich, immunothrombosis, inflammation, InTraC, Johannes Gutenberg University Mainz, Konstantin Stark, LMU, LMU Secures Major German Research Funding for New Thrombosis and Inflammation Research Consortium, LMU University Hospital, Ludwig Maximilian University of Munich, Matthias Tschöp, Max Planck Institute of Biochemistry, medical research, New Collaborative Research Centre at LMU to Explore Immune and Blood Clotting Interactions in Disease, nucleic acid immunity, RNA therapy, Steffen Massberg, stroke, systems biology, thromboinflammatory disease, thrombosis, translational medicine, University of Münster, University of Würzburg, venous thromboembolism
(IN BRIEF) Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an investigational monoclonal antibody currently in Phase 3 trials for preventing stroke and systemic embolism in patients with atrial fibrillation. This acquisition … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged abelacimab, acquisition, Anthos Therapeutics, anticoagulation, atrial fibrillation, biopharmaceutical company, Blackstone Life Sciences, bleeding reduction, Boston, cancer-associated thrombosis, cardiovascular, cardiovascular therapeutic area, clinical-stage, David Soergel, Factor XI inhibition, Fast Track Designation, FDA, medical research, Novartis, partnership, Phase 3 trials, regulatory milestones, Shreeram Aradhye, stroke prevention, systemic embolism, therapeutic focus, thrombosis
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?